Clinically, DLBCL patients with high JAM-A expression displayed a remarkable increase in tumor CD133 positivity (+++~++++) than those of low JAM-A expression (P = 0.0048, Fig. 2D). This evidence concerns the gene PROM1 and neoplasm.